Research area
Health & Longevity
Human health, disease, treatment and aging. The largest corpus area supports distinct cancer, neurological and therapeutic navigation.
-
Evidence date ·What changed when immune checkpoint drugs joined cancer treatment?
Review or Meta-AnalysisA 19-trial review found better survival and response rates with added checkpoint drugs, while time to response showed no significant difference and severe side effects rose slightly.
-
Evidence date ·US studies used different benchmarks for advanced lung cancer drugs
Review or Meta-AnalysisIn 28 US lung cancer drug analyses, median cost-effectiveness thresholds were $150,000 in industry-supported studies and $100,000 in nonprofit-supported studies.
-
Evidence date ·What can remain after high-grade glioma treatment?
Review or Meta-AnalysisA 2021 review explains how glioblastoma cells can extend beyond the visible tumor and vary within it, complicating surgery and efforts to tailor treatment.
-
Evidence date ·A tumor’s response to immune treatment is a changing story
Review or Meta-AnalysisA melanoma study linked a week-four drop in tumor mutation count with response to nivolumab. The review also traces how tumors can evade immune attack.
-
Evidence date ·Why does MSI-high matter more in some colorectal cancer stages?
Review or Meta-AnalysisA 2021 meta-analysis linked high microsatellite instability with less spread overall; survival differences were clearest in stages II and III.
-
Evidence date ·Why is holding adenoid cystic carcinoma steady easier than making it respond?
Review or Meta-AnalysisA 2021 review describes mostly stable disease across adenoid cystic carcinoma treatments and points to weak immune recognition as a barrier to checkpoint drugs.
-
Evidence date ·After CAR-T remission, could a stem cell transplant help it last?
Review or Meta-AnalysisA 2021 review of 18 studies linked stem cell transplant after CAR-T to fewer relapses and better survival, but found no clear overall-survival benefit in two subgroups.
-
Evidence date ·Who was the afatinib study about, and what counted as a response?
Clinical TrialPhysicians' charts and tumor measurements offer two ways to count response in this afatinib study. Its broad title and lung cancer listing leave the patient mix unclear.
-
Evidence date ·What lets some tumor-fighting T cells sustain a response?
Review or Meta-AnalysisCheckpoint drugs rely in part on a lasting supply of tumor-fighting T cells. A 2021 review explains why cell state and tumor access matter.
-
Evidence date ·What can a tumor response tell someone with advanced cancer of the upper urinary tract?
Review or Meta-AnalysisA 2021 review found a 21.2% tumor response rate with immunotherapy in upper urinary tract cancer; it did not establish a survival benefit over platinum chemotherapy.